Last week, the results of ORBITA were published. This clinical trial tested coronary angioplasty and stenting versus optimal medical management in patients with single-vessel coronary artery disease. It was a resoundingly negative trial, meaning that adding stenting to drug management didn’t result in detectable clinical improvement. What was distinctive about this trial is that it used a sham procedure (i.e., placebo) control, which few trials testing surgery or a procedure use. The results of ORBITA emphasize how important sham procedure controls are, whenever they can be ethically used, and how resistant physicians can be to change.
Search: “how they view us”
We found 3,548 results for your search.
Southeast Michigan is currently in the midst of a hepatitis A outbreak that started in August 2016. In Algonac, a small town in the Thumb region, the mayor decided to help a restaurant whose business suffered when one of its new staff members under training caught hepatitis A. Unfortunately, the form that help took was to host an antivaccine propaganda meeting.
Share this:
Orac is back, and what does he encounter upon his return? Barbara Loe Fisher, founder of the Orwellian-named antivaccine propaganda organization, the National Vaccine Information Center, pontificating about “informed consent” and vaccines. What she really means is misinformed consent to refuse vaccines, as in consent based on misinformation, pseudoscience, and fear mongering about vaccines. Naturally, she can’t resist bringing in Nazis as well.
Share this:
Ever since the $200 million gift by Susan and Henry Samueli to UC-Irvine, I’ve been thinking about the “integration” of quackery into medicine through integrative medicine. The way advocates of quackademic medicine are going to make this “integration” really happen is to start with the medical schools.
Share this:
My skeptical analysis of Rigvir, a “Virotherapy” from Latvia being promoted by alternative medicine clinics as a cancer cure, caught the attention of the International Virotherapy Center (IVC). The result was a long and very telling e-mail exchange between its Assistant of Business Development and myself. I post it because the arguments used in the discussion are very telling about where the IVC is coming from when it comes to science. Hint: It’s not a good place.
